The FDA approved ensartinib for the treatment of certain patients with ALK-positive locally advanced or metastatic non-small cell lung cancer. The indication applies to use of the agent for adults not ...
Lung cancer is one of the kinds of cancer that is most likely to spread to the brain. Approximately 20 percent of lung cancer patients develop brain metastases. And roughly 10 to 20 percent of people ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
Thoracic medical oncologists and early drug development specialists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for this patient population.
Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for reflexive ...
Deaths from cancer have fallen dramatically. They’ve dropped by 34% over the past three decades — largely thanks to better treatments, earlier detection, and fewer people smoking. But cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback